Autres langues ImmunityBio, Inc.

Actions

IBRX

US45256X1037

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
6,1 ^USD	+0,16 %		-4,98 %	+21,51 %

09/05	ImmunityBio, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
07/05	Les actions d'ImmunityBio augmentent après l'achèvement de la fabrication de la substance médicamenteuse pour le traitement du cancer	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update	07/06
ImmunityBio - Connecting the Dots of ANKTIVA's Triangle Offense, A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast	20/05
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast	17/05
ImmunityBio: Q1 Earnings Snapshot	10/05
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	07/05
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	07/05
ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	07/05
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	06/05
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline	03/05
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types	02/05
Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types	02/05
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA Approval in Fireside Chat at the Annual Conference of the American Urological Association	01/05
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association	30/04
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline	30/04
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	29/04
ImmunityBio : Investor Live Audio Webcast – ANKTIVA Post Approval	27/04
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer	26/04
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer	25/04
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	25/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ImmunityBio, Inc.

Actions

IBRX

US45256X1037

Autres langues

Filtres